Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27666541 | 1.00 | EPHX1 (0.60) | EPHX1CA12CA1CA2MMP2 | |
| SCHEMBL931217 | 1.00 | EPHX1 (0.60) | EPHX1CA12CA1CA2MMP2 | |
| SCHEMBL2055562 | 1.00 | EPHX1 (0.60) | EPHX1CA12CA1CA2MMP2 | |
| Hydrochloric Acid SCHEMBL6758598 | 0.98 | EPHX1 (0.58) | EPHX1CA12CA1CA2MMP2 | |
| SCHEMBL5973016 | 0.98 | EPHX1 (0.58) | EPHX1CA12CA1CA2MMP2 | |
| Hydrochloric Acid SCHEMBL5392442 | 0.98 | EPHX1 (0.58) | EPHX1CA12CA1CA2MMP2 | |
| SCHEMBL930716 | 0.98 | EPHX1 (0.56) | EPHX1CA12CA1CA2MMP2 | |
| Hydrochloric Acid SCHEMBL5928655 | 0.96 | EPHX1 (0.56) | EPHX1CA12CA1CA2MMP2 | |
| SCHEMBL930588 | 0.93 | — | — | |
| SCHEMBL11682920 | 0.87 | ALOX5 (0.48) | EPHX1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106518808-A | 3-(N, N-disubstituted amino) propanamide derivative and preparation method and use thereof in medicine | 沈阳药科大学 | 2017-03-22 | — | — | CN | claimed |
| WO-2011000945-A2 | AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS | NENSIUS RESEARCH A/S (DK) | 2011-01-06 | — | — | WO | claimed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | claimed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | claimed |
| EP-1844030-A1 | CYCLOHEXYLAMIDES AS DOPAMINE D3 , D2 AND 5HT1A ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2007-10-17 | — | — | EP | claimed |
| EP-1187613-B9 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2006082456-A1 | CYCLOHEXYLAMIDES AS DOPAMINE D3 , D2 AND 5HT1A ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-08-10 | — | — | WO | claimed |
| EP-1187613-B1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-08-09 | — | — | EP | claimed |
| CN-1720047-A | PgD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2006-01-11 | — | — | CN | claimed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | claimed |
| CN-1436175-A | Cyclic lactams as inhibitors of A beta-protein production | BRISTOL MYERS SQUIBB PHARMACEU (US) | 2003-08-13 | — | — | CN | claimed |
| CN-1353609-A | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2002-06-12 | — | — | CN | claimed |
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | PMV PHARMACEUTICALS, INC. | 2024-04-11 | — | — | US | disclosed |
| CN-111763428-B | Polyimide film and flexible display device cover substrate using same | 律胜科技股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-10954236-B2 | Tyrosine amide derivatives as Rho-Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-03-23 | — | — | US | disclosed |
| US-10624882-B2 | Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| EP-0858444-A1 | CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997014671-A1 | CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | disclosed |
| US-4835312-A | Production process of N-substituted amide compounds | MITSUI CHEMICALS, INCORPORATED (JP) | 1989-05-30 | — | — | US | disclosed |
| US-4263293-A | ANTIARTHRITIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954236-B2 | Tyrosine amide derivatives as Rho-Kinase inhibitors | ROCK1, ROCK2, CIT | EPHX1 810/4885CA12 4291/4885CA1 4062/4885 |
| US-10624882-B2 | Rho kinase inhibitors | ROCK1, ROCK2, CIT | EPHX1 832/4885CA12 4885/4885CA1 4843/4885 |
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | WAPL, WHR1, G3BP1 | EPHX1 1796/4885CA12 4637/4885CA1 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.